Company facts
- Headquarters
- New York, New York
- Most recent report
- 8-K, filed Sep 8, 2026
- Filings on record
- 485 filings
- On EDGAR
- CIK 1813814
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 65
News 8 of 80
Prospectuses and Registrations 8 of 21
- 424B5 Prospectus supplement for an offering Jun 24, 2026
- 424B5 Prospectus supplement for an offering Jun 22, 2026
- S-8 Registration statement for an employee plan Jun 16, 2026
- 424B5 Prospectus supplement for an offering Oct 31, 2025
- 424B5 Prospectus supplement for an offering Oct 29, 2025
- S-8 Registration statement for an employee plan Jun 20, 2025
- 424B3 Prospectus supplement for an offering Oct 22, 2024
- 424B5 Prospectus supplement for an offering Aug 12, 2024
Proxies 8 of 35
- DEFA14A Extra proxy material Apr 27, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 27, 2026
- DEFA14A Extra proxy material Apr 23, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 23, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- DEFA14A Extra proxy material Jun 16, 2023
- DEFA14A Extra proxy material Jun 15, 2023
Ownership 8 of 235
- 4 Insider reported a trade Sep 4, 2026
- 144 Notice of a proposed sale of restricted stock Sep 3, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
Other 8 of 49
Everything here comes from Definium Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.